Home > Search Clinical Trials > Breathing and Lung
Clinical Trials: Breathing and Lung
IRB No. 12-009-2 (Dr. Mark Metersky, PI): Bronchiectasis Research Registry: A Consolidated Database of Non-Cystic Fibrosis Bronchiectasis Patients from Major Clinical and Research Institutions
Study description not available
IRB No. 17-045J-2 (Dr. Mario Perez, PI): The Airway Inflammatory Profile of E-Cigarette Users
Study objective: The reserach study is about how the human body, particularly the airways, react to the regular use of e-cigarettes. The purpose is to show that regular use of e-cigarettes can be associated with airway inflammation in the sputum of regular users of e-cig. We intend to study if the regular use of e-cig, in a simliar way to conventional cigarettes, can trigger an inflammatory response in the airways. Hypotheses: 1. subjects who use e-cigarettes have evidence of airway inflammation when compared to healthy non-smoker subjects 2. Subjects who smoke regular tobacco cigarettes have evidence of more airway inflammaiton than e-cigarette users. 3. Subjects who use e-cigs with flavoring, e.g. chocolate, or regular cigarettes with flavoring (e.g. menthol) will have more airway inflammation than e-cig and regular cigarette users who don't use flavored products, e.g. menthol. Aims: 1. We plan to characterize airway inflammation profile in e-cig users compared to healthy non-smokers 2. We plan to characterize the airway inlfammatory profile of tobacco cigarette smokers compared to e-cig users. 3. We plan to characterize the effect of menthol in e-cigarettes and tobacco cigarettes on the airway inflammatory profile.
IRB No. 24-094-1 (Dr. Omar Ibrahim, PI): Before-After Operational Data Collection Study Protocol - UConn
The diagnosis managment of lung nodules can be difficult. Current guidelines recommend that pulmonary nodules are managed based upon their probability of malignancy. Despite established guidelines, prior studies estimate that 60-70% of patients with ILNs are not followed up in a timely fashion in accordance with guidelines. To address the management and diagnostic challenges, Optellum has developed Virtual Nodule Clinic (VNC). VNC is an FDA-cleared, web-based, end-to-end software solution early lung cancer diagnosis. University of Connecticut Health (UConn) will be using VNC for routine clinical management of pulmonary nodule patients. As such, UConn offers an ideal environment in which to evaluate the real-world clinical utility of VNC. As part of this partnership, UConn will work with Optellum to evaluate whether use of VNC leads to an improvement in the number of pulmonary nodule patients being followed up and in the pulmonary nodule care pathway. All patients enrolled in UConn';s pulmonary nodule clinic will be eligible. The number of subjects with data collection is unspecified and will depend on the number of patients seen during different phases of the study. The data collection will have three parts: Phase 1: Baseline pre-VNC installation: operational data will be extracted from patient charts up to 6 months prior to the ';Go live'; date of Optellum';s VNC at UConn. Ramp-up period: This is the period during which UConn VNC users are being trained and migrating from their existing workflow, while the VNC workflow is being customized to their feedback. Phase 2: Active Patient Discovery post-VNC installation: operational data will be collected for the 3-12 months post-installation of VNC. During this time the Patient Discovery feature of VNC will be in active use by UConn VNC users.